Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
EARLY_PHASE1
40 participants
INTERVENTIONAL
2024-05-01
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the current study are:
1. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in healthy individuals.
2. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in patients with alpha synuclein aggregates in the brain, including PD, DLB and MSA.
3. To determine human dosimetry of \[11C\]SY08 in healthy individuals
An intravenous bolus injection of \[11C\]SY08 will be administered per subject for brain PET imaging.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
evaluation of alpha synuclein aggregates in the brain
C11-SY08
a PET imaging agent
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
C11-SY08
a PET imaging agent
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Be able to provide written informed consent or assent
3. Be able to read, speak and understand English (The investigators do not have the resources necessary to properly study non-English speaking patients in this study, given that translation and validation of the assessment tools would be necessary)
4. Be willing and able to participate in one PET/MRI scanning session
1. Have an existing diagnosis of idiopathic PD, using consensus criteria
2. Stable medications for at least 30 days
3. Hoehn and Yahr stage I-IV
4. A study partner who can answer questions pertaining to daily functioning
1. Have an existing diagnosis of MSA, using consensus criteria
2. Stable medications for at least 30 days
3. MSAp or MSAc
4. A study partner who can answer questions pertaining to daily functioning
1. Have an existing diagnosis of probable DLB, using consensus criteria
2. Stable medications for at least 30 days
3. Clinical Dementia Rating Scale (CDR) \< 0.5
4. A study partner who can answer questions pertaining to daily functioning
Exclusion Criteria
2. Major psychiatric disease (e.g.schizophrenia)
3. History of stroke
4. Focal brain lesions on MRI scans
5. History of other major illnesses including, but not limited to, major kidney or liver problems or significant neurological illness
6. Recent surgery that is deemed major by our reviewing physician or nurse practitioner within the past 6 months
7. History of head trauma (as defined as having any insults to the brain that may have resulted from an external mechanical force, such as rapid acceleration or deceleration, impact, blast waves, or penetration by a projectile)
8. Impaired elimination (as defined as having problems with urination) unless being managed
9. Past or present diagnosis of bipolar disorder or other Axis I diagnosis, (treated depression is allowed)
10. Any present substance abuse including drug/alcohol abuse
11. Inability to lie flat on camera bed for up to 90 min
12. Pregnancy or breastfeeding
13. Metallic foreign bodies that would be affected by the MRI magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan
14. Recent exposure to radiation (i.e., PET from other research) that, when combined with this study, would be above the allowable limits (50 milliSieverts)
1. Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, steel implants, ferromagnetic objects such as jewelry or metal clips in clothing
2. Electrical implants such as cardiac pacemakers or perfusion pumps
3. Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
4. Is unable to lie comfortably on a bed inside a PET camera with their head in the field of view for 60 to 90 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis)
5. Pregnancy: A negative serum pregnancy test is required on the day of the PET procedure in women of child bearing potential
6. Body weight of \> 300 lbs (weight limit of the MRI table)
7. Breast feeding mothers
1. An abnormal result on the modified Allen's test on both hands
2. Raynaud syndrome
3. Bleeding disorder
4. Use of anticoagulants such as Coumadin, Plavix or Lovenox
5. An allergy to Lidocaine
50 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Changning Wang
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MGH
Charlestown, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Changning Wang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023P002302
Identifier Type: -
Identifier Source: org_study_id